Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ciclopirox
Drug ID BADD_D00461
Description Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Indications and Usage Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum.
Marketing Status approved; investigational
ATC Code D01AE14; G01AX12
DrugBank ID DB01188
KEGG ID D03488
MeSH ID D000077768
PubChem ID 2749
TTD Drug ID D07GRH
NDC Product Code 50090-6562; 63629-8620; 63629-8621; 68788-6797; 0574-2061; 0591-2159; 49706-1440; 99207-010; 51014-7851; 42192-714; 43538-500; 45802-141; 63629-8623; 42192-715; 50383-419; 51672-1351; 63629-8622; 68462-455; 64552-8110; 0713-0317; 17337-0506; 71052-661; 45802-401; 51672-1323; 51672-5302
UNII 19W019ZDRJ
Synonyms Ciclopirox | Cyclopirox | HOE 296 | HOE-296 | HOE296 | Ciclopirox Olamine | Cyclopyroxolamine | 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt | Ciclopiroxolamine | Loprox | Batrafen | Penlac | Dafnegin-CSC | Dafnegin CSC
Chemical Information
Molecular Formula C12H17NO2
CAS Registry Number 29342-05-0
SMILES CC1=CC(=O)N(C(=C1)C2CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alopecia23.02.02.001--
Application site irritation12.07.01.003; 08.02.01.003--Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Condition aggravated08.01.03.004--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Drug ineffective08.06.01.006--Not Available
Dry skin23.03.03.001--
Eczema23.03.04.006--
Erythema23.03.06.001--Not Available
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Hair colour changes23.02.06.001--
Hair texture abnormal23.02.06.004--
Headache17.14.01.001--
Immune system disorder10.02.01.001--Not Available
Ingrowing nail23.02.05.011--Not Available
Irritability19.04.02.013; 08.01.03.011--
Nail discolouration23.02.05.001--
Nail disorder23.02.05.002--
Pain08.01.08.004--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Ventricular tachycardia02.03.04.010--
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene